Can-Fite BioPharma stock surged over 40% pre-market after reporting positive results from a Phase 2A study of namodenoson in advanced pancreatic cancer. The trial met its primary safety endpoint, showing the drug was well tolerated with no new concerns. The selective A3 adenosine receptor agonist has received Orphan Drug Designation from the FDA for this indication.